跳轉至內容
Merck
全部照片(1)

重要文件

C-116

Supelco

Clomipramine-d3 hydrochloride solution

100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

同義詞:

Clomipramine-D3 hydrochloride solution

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C19D3H20ClN2 · HCl
CAS號碼:
分子量::
354.33
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24
暫時無法取得訂價和供貨情況

等級

certified reference material

品質等級

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

100 μg/mL in methanol (as free base)

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

儲存溫度

−20°C

SMILES 字串

Clc1cc2c(cc1)CCc3c(cccc3)N2CCCN(C([2H])([2H])[2H])C.Cl

InChI

1S/C19H23ClN2.ClH/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22;/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3;1H/i1D3;

InChI 密鑰

WIMWMKZEIBHDTH-NIIDSAIPSA-N

一般說明

Clomipramine is a tricyclic antidepressant used to many conditions from major depression and panic disorder to narcolepsy and obsessive compulsion disorder (OCD). This internal standard is is suitable for quantitation of Clomipramine levels in urine, serum, or plasma by LC/MS or GC/MS for applications in clinical toxicology, forensic analysis, isotope dilution methods, or pharmaceutical research.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Luiza G Tunes et al.
ACS infectious diseases, 6(5), 1121-1139 (2020-04-15)
The drugs currently used to treat leishmaniases have limitations concerning cost, efficacy, and safety, making the search for new therapeutic approaches urgent. We found that the gold(I)-derived complexes were active against L. infantum and L. braziliensis intracellular amastigotes with IC50 values ranging

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務